Drugs / AST-726
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00285402 | May 2007 → Jun 2008 | migraine with aura, migraine without aura | Ariston Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AST-726 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00285402 ↗ |
| Route | Intranasal | “AST-726 and the placebo will be self-administered by intranasal spray daily for 12 weeks.” NCT00285402 ↗ |